TargetBeta
IL13
interleukin 13 · also P600, IL-13, ALRH, BHR1 · Interleukins
7 programs in company-led studies act on IL13, from 5 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| lebrikizumabrule | Eli Lilly | phase 4 | 447 running | – | NCIt |
| tilrekimig | Pfizer | phase 3 | 119 running | IL4, TSLP | the company's pipeline |
| lunsekimig | Sanofi | phase 3 | 106 running | TSLP | the company's pipeline |
| zumilokibart | AbbVie | phase 2 | 44 running | – | the company's pipeline |
| ompekimig | Pfizer | phase 2 | 31 running | IL33, IL4 | the company's pipeline |
| GHZ339 | Novartis | phase 2 | 11 running | IL18 | the company's pipeline |
| ABBV-313 | AbbVie | phase 1 | 11 running | IL31RA | the company's pipeline |
Conditions their studies are in
- Dermatitis, Atopic, 6 programs
- Asthma, 4 programs
- Pulmonary Disease, Chronic Obstructive, 3 programs
- Nasal Polyps, 2 programs
- Rhinitis, Allergic, Perennial, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026zumilokibart · AbbVie · phase 2 · NCT06395948
- Feb 20, 2027tilrekimig · Pfizer · phase 3 · NCT07792941
- Apr 25, 2027lebrikizumab · Eli Lilly · phase 4 · NCT06526182
- Jun 21, 2027lunsekimig · Sanofi · phase 3 · NCT06676319
- Feb 2028ABBV-313 · AbbVie · phase 1 · NCT07673120
- Nov 27, 2028GHZ339 · Novartis · phase 2 · NCT06947993
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.